Thomas Raffin, MD

Tom has served on the Akoya Board of Directors since the inception of Akoya Biosciences. Tom spent 24 years on the faculty at Stanford University School of Medicine where he remains the Colleen and Robert Haas Professor Emeritus of Medicine and Biomedical Ethics, former Chief of Pulmonary and Critical Care Medicine, and Co-Founder and Director Emeritus of the Stanford University Center for Biomedical Ethics. Over the past two decades he has worked extensively in the healthcare and medical device sectors and is a co-founder of Rigel Pharmaceuticals. In addition to Akoya, Tom has represented THP on the boards AngioScore (acquired by Spectranetics), Aquaro, Confirma (acquired by Merge), LDR Spine (NASDAQ:LDRH), PneumRx (acquired by BTG Plc), Freedom Innovations (acquired by Health Evolution Partners) and Magstim. He was an observer on the boards of Estech (acquired by AtriCure) and Vidacare (acquired by Teleflex). Tom received a BA from Stanford University and an M.D. from Stanford University School of Medicine and completed his medical residency at the Peter Bent Brigham Hospital in Boston.